Cargando…

A single dose polyanhydride-based nanovaccine against paratuberculosis infection

Mycobacterium avium subsp. paratuberculosis (M. paratuberculosis) causes Johne’s disease in ruminants and is characterized by chronic gastroenteritis leading to heavy economic losses to the dairy industry worldwide. The currently available vaccine (inactivated bacterin in oil base) is not effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Thukral, Akanksha, Ross, Kathleen, Hansen, Chungyi, Phanse, Yashdeep, Narasimhan, Balaji, Steinberg, Howard, Talaat, Adel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021715/
https://www.ncbi.nlm.nih.gov/pubmed/32128256
http://dx.doi.org/10.1038/s41541-020-0164-y
_version_ 1783497930185900032
author Thukral, Akanksha
Ross, Kathleen
Hansen, Chungyi
Phanse, Yashdeep
Narasimhan, Balaji
Steinberg, Howard
Talaat, Adel M.
author_facet Thukral, Akanksha
Ross, Kathleen
Hansen, Chungyi
Phanse, Yashdeep
Narasimhan, Balaji
Steinberg, Howard
Talaat, Adel M.
author_sort Thukral, Akanksha
collection PubMed
description Mycobacterium avium subsp. paratuberculosis (M. paratuberculosis) causes Johne’s disease in ruminants and is characterized by chronic gastroenteritis leading to heavy economic losses to the dairy industry worldwide. The currently available vaccine (inactivated bacterin in oil base) is not effective in preventing pathogen shedding and is rarely used to control Johne’s disease in dairy herds. To develop a better vaccine that can prevent the spread of Johne’s disease, we utilized polyanhydride nanoparticles (PAN) to encapsulate mycobacterial antigens composed of whole cell lysate (PAN-Lysate) and culture filtrate (PAN-Cf) of M. paratuberculosis. These nanoparticle-based vaccines (i.e., nanovaccines) were well tolerated in mice causing no inflammatory lesions at the site of injection. Immunological assays demonstrated a substantial increase in the levels of antigen-specific T cell responses post-vaccination in the PAN-Cf vaccinated group as indicated by high percentages of triple cytokine (IFN-γ, IL-2, TNF-α) producing CD8(+) T cells. Following challenge, animals vaccinated with PAN-Cf continued to produce significant levels of double (IFN-γ, TNF-α) and single cytokine (IFN-γ) secreting CD8(+) T cells compared with animals vaccinated with an inactivated vaccine. A significant reduction in bacterial load was observed in multiple organs of animals vaccinated with PAN-Cf, which is a clear indication of protection. Overall, the use of polyanhydride nanovaccines resulted in development of protective and sustained immunity against Johne’s disease, an approach that could be applied to counter other intracellular pathogens.
format Online
Article
Text
id pubmed-7021715
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70217152020-03-03 A single dose polyanhydride-based nanovaccine against paratuberculosis infection Thukral, Akanksha Ross, Kathleen Hansen, Chungyi Phanse, Yashdeep Narasimhan, Balaji Steinberg, Howard Talaat, Adel M. NPJ Vaccines Article Mycobacterium avium subsp. paratuberculosis (M. paratuberculosis) causes Johne’s disease in ruminants and is characterized by chronic gastroenteritis leading to heavy economic losses to the dairy industry worldwide. The currently available vaccine (inactivated bacterin in oil base) is not effective in preventing pathogen shedding and is rarely used to control Johne’s disease in dairy herds. To develop a better vaccine that can prevent the spread of Johne’s disease, we utilized polyanhydride nanoparticles (PAN) to encapsulate mycobacterial antigens composed of whole cell lysate (PAN-Lysate) and culture filtrate (PAN-Cf) of M. paratuberculosis. These nanoparticle-based vaccines (i.e., nanovaccines) were well tolerated in mice causing no inflammatory lesions at the site of injection. Immunological assays demonstrated a substantial increase in the levels of antigen-specific T cell responses post-vaccination in the PAN-Cf vaccinated group as indicated by high percentages of triple cytokine (IFN-γ, IL-2, TNF-α) producing CD8(+) T cells. Following challenge, animals vaccinated with PAN-Cf continued to produce significant levels of double (IFN-γ, TNF-α) and single cytokine (IFN-γ) secreting CD8(+) T cells compared with animals vaccinated with an inactivated vaccine. A significant reduction in bacterial load was observed in multiple organs of animals vaccinated with PAN-Cf, which is a clear indication of protection. Overall, the use of polyanhydride nanovaccines resulted in development of protective and sustained immunity against Johne’s disease, an approach that could be applied to counter other intracellular pathogens. Nature Publishing Group UK 2020-02-14 /pmc/articles/PMC7021715/ /pubmed/32128256 http://dx.doi.org/10.1038/s41541-020-0164-y Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Thukral, Akanksha
Ross, Kathleen
Hansen, Chungyi
Phanse, Yashdeep
Narasimhan, Balaji
Steinberg, Howard
Talaat, Adel M.
A single dose polyanhydride-based nanovaccine against paratuberculosis infection
title A single dose polyanhydride-based nanovaccine against paratuberculosis infection
title_full A single dose polyanhydride-based nanovaccine against paratuberculosis infection
title_fullStr A single dose polyanhydride-based nanovaccine against paratuberculosis infection
title_full_unstemmed A single dose polyanhydride-based nanovaccine against paratuberculosis infection
title_short A single dose polyanhydride-based nanovaccine against paratuberculosis infection
title_sort single dose polyanhydride-based nanovaccine against paratuberculosis infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021715/
https://www.ncbi.nlm.nih.gov/pubmed/32128256
http://dx.doi.org/10.1038/s41541-020-0164-y
work_keys_str_mv AT thukralakanksha asingledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT rosskathleen asingledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT hansenchungyi asingledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT phanseyashdeep asingledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT narasimhanbalaji asingledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT steinberghoward asingledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT talaatadelm asingledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT thukralakanksha singledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT rosskathleen singledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT hansenchungyi singledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT phanseyashdeep singledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT narasimhanbalaji singledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT steinberghoward singledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection
AT talaatadelm singledosepolyanhydridebasednanovaccineagainstparatuberculosisinfection